Page 12 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers
P. 12
Management Algorithm (3/3)
IO naïve IO experienced
FGFR gene alteration FGFR gene alteration FGFR gene alteration FGFR gene alteration
SECOND- LINE positive negative positive negative
THERAPY
METASTATIC
UROTHELIAL IO therapy § Chemotherapy
CARCINOMA
Alternative: FGFR IO therapy § OR Chemotherapy
inhibitor therapy FGFR inhibitor therapy
(erdafitinib) (erdafitinib)
THIRD- LINE Consider previously unused treatments or clinical trials,
THERAPY IO, chemotherapy (paclitaxel, docetaxel)
METASTATIC
UROTHELIAL
CARCINOMA Alternatives pending Health Canada Approval
Enfortumab vedotin ♦
§ Approved for 2L; ♦ Enfortumab vedotin anticipated approval is for post chemo/post IO therapy
FGFR, fibroblast growth factor receptor; IO, immuno-oncology; PD-L1, programmed death ligand 1.
